An Open Label, Registry Study of the Safety of Iluvien 190 Micrograms Intravitreal Implant in Applicator

Trial Profile

An Open Label, Registry Study of the Safety of Iluvien 190 Micrograms Intravitreal Implant in Applicator

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Acronyms IRISS
  • Sponsors Alimera Sciences
  • Most Recent Events

    • 19 Jul 2017 According to a Alimera Sciences media release, Alimera enrolled the 550th patient in January 2017, making the anticipated last patient, last visit date in January 2020.
    • 19 Jul 2017 According to a Alimera Sciences media release, the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) has given final approval to reduce the sample size of this ILUVIEN Registry Safety Study (IRISS) to 550.
    • 08 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top